Compare Crispr Therapeutics AG (CRSP) vs KraneShares Hang Seng TECH Index ETF (KTEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs KraneShares Hang Seng TECH Index ETF — how do they compare? Crispr Therapeutics AG trades at $50.73 (market cap $4.97B), while KraneShares Hang Seng TECH Index ETF trades at $13.28. Which is the better fit depends on your goals.
| CRSP | KTEC | |
|---|---|---|
Market Cap | $4.97B | — |
Sector | Health | Sector/Thematic |
52-Week High | $76.78 | $19.51 |
52-Week Low | $44.34 | $12.00 |
Enterprise Value | $3.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
KTEC trades at $12.90, down 1.07% with mixed technical signals showing bullish moving averages but overbought RSI conditions. The stock faces consolidation near key support/resistance at $13. Fundamental data remains limited pending updated financial disclosures from recent SEC filings.
The technical setup suggests near-term consolidation while awaiting fundamental catalysts. Investment opportunity depends on upcoming earnings validation, though limited institutional coverage and thin financial data increase reliance on technical momentum for directional bias.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About KraneShares Hang Seng TECH Index ETF
KTEC tracks the Hang Seng TECH Index, providing targeted exposure to the 30 largest technology companies listed on the Hong Kong Stock Exchange. It focuses on innovative, internet-based businesses across sectors like e-commerce, fintech, cloud computing, and digital technology.
Read more on KTEC →
